MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
It is the first autotaxin inhibitor to be investigated in cancer patients
Subscribe To Our Newsletter & Stay Updated
